Intellia Therapeutics (NASDAQ:NTLA) Cut to “Sell” at Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

NTLA has been the topic of several other reports. Evercore ISI set a $8.00 target price on shares of Intellia Therapeutics and gave the stock an “in-line” rating in a research note on Tuesday, November 11th. Wolfe Research restated a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. Guggenheim cut Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Bank of America lowered their target price on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Robert W. Baird set a $9.00 price target on Intellia Therapeutics in a report on Thursday, October 30th. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and an average price target of $18.43.

Intellia Therapeutics Trading Down 1.6%

NTLA opened at $9.44 on Friday. The stock’s 50-day moving average price is $11.48 and its 200 day moving average price is $12.64. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -2.21 and a beta of 2.13.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.34) EPS. On average, research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new position in Intellia Therapeutics in the second quarter valued at approximately $26,000. Blue Bell Private Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Whipplewood Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after buying an additional 3,447 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.